Position in CADL
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$694,178
+$364,678 QoQ
Shares Held
67,396
+0.2% QoQ
Ownership
0.088%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#42
of 138 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HB Wealth Management, LLC holds $35,016,992 across 39 Biotechnology names. CADL ranks #11 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
50,440 | $12,346,198 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
11,065 | $5,496,317 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,712 | $1,691,040 | |
| 4 | EXEL |
Exelixis, Inc.
|
26,737 | $1,454,760 | |
| 5 | SABS |
SAB Biotherapeutics, Inc.
|
307,500 | $1,199,250 | |
| 6 | RPRX |
Royalty Pharma plc
|
20,240 | $1,134,856 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
14,202 | $1,111,590 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
5,336 | $999,326 |
All Filings in CADL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $694,178 | 67,396 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $329,500 | 67,245 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $329,649 | 58,345 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $297,559 | 58,345 | Shares | Sole | 2025-10-23 | |
| 2025-03-31 | $532,795 | 94,300 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $757,764 | 87,300 | Shares | Sole | 2025-01-15 | |
| 2024-09-30 | $392,639 | 56,658 | Shares | Sole | 2024-10-15 | |
| No filing history on record for this holder in this stock. | ||||||